AQST

AQST R&D Expenses

$15.89MTTM · USD

Period ending:

AQST FY R&D ExpensesUSD
AQST FY R&D Expenses2016-12-31: $15.45M2017-12-31: $22.13M2018-12-31: $23.11M2019-12-31: $20.57M2020-12-31: $19.89M2021-12-31: $17.05M2022-12-31: $17.48M2023-12-31: $13.10M2024-12-31: $20.28M2025-12-31: $17.19M$23.11M$0.00
2016-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

AQST r&d expenses history

Research and development spending. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.

Aquestive Therapeutics Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
17,192,000
20,280,000
13,104,000
17,481,000
17,047,000
19,886,000
20,574,000
23,112,000
22,133,000
15,450,000

Compare r&d expenses

All AQST financial metrics · AQST stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.